Royalty Rates in Biotech Deals, Part I
Executive Summary
Royalty rates in biotech deals are determined by a variety of factors; most important is the level of risk the product represents at the stage it is licensed.
You may also be interested in...
Neurology At The Forefront Of US FDA Complex Innovative Trial Design Pilot
Wave’s Duchenne muscular dystrophy drug and Lilly’s chronic pain R&D will test the agency’s CID meeting pilot program, while FDA issues draft guidance that highlights potential uses for complex innovative trial designs.
US FDA And Sponsors Resolve Disclosure Issues On Complex Trial Design Pilot Projects
Agency officials can now discuss the ideas that have been accepted, though not in great detail.
US FDA Requests Ranitidine Removal But Also Encourages Research For Stable Formulations
FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.
Need a specific report? 1000+ reports available
Buy Reports